1. Home
  2. SEED vs BRTX Comparison

SEED vs BRTX Comparison

Compare SEED & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Agritech Limited

SEED

Origin Agritech Limited

N/A

Current Price

$1.17

Market Cap

12.6M

ML Signal

N/A

Logo BioRestorative Therapies Inc. (NV)

BRTX

BioRestorative Therapies Inc. (NV)

N/A

Current Price

$0.28

Market Cap

9.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SEED
BRTX
Founded
1997
1997
Country
China
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Managed Health Care
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.6M
9.3M
IPO Year
2005
2015

Fundamental Metrics

Financial Performance
Metric
SEED
BRTX
Price
$1.17
$0.28
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
15.9K
6.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
66.08
EPS
N/A
N/A
Revenue
N/A
$81,000.00
Revenue This Year
N/A
$24.64
Revenue Next Year
N/A
$287.76
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$0.19
52 Week High
$2.49
$2.10

Technical Indicators

Market Signals
Indicator
SEED
BRTX
Relative Strength Index (RSI) 61.22 30.57
Support Level $0.95 $0.19
Resistance Level $1.38 $0.29
Average True Range (ATR) 0.11 0.03
MACD 0.02 0.03
Stochastic Oscillator 57.17 89.35

Price Performance

Historical Comparison
SEED
BRTX

About SEED Origin Agritech Limited

Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.

About BRTX BioRestorative Therapies Inc. (NV)

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

Share on Social Networks: